Etcembly
Etcembly is a UK-based AI-native techbio company whose EMLy Co-pilot platform unifies antibody and T-cell receptor design workflows into a single conversational interface, serving biotech and pharma R&D organizations with proprietary structural modeling, variant generation, and biologics optimization capabilities.
- Company typePrivate
- Founded2020
- HeadquartersHanwell, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Etcembly does
Etcembly Limited is a UK-based techbio company founded in 2020 and headquartered at the Harwell Campus in Oxfordshire, building AI tooling for biologics discovery. Its core product, EMLy Co-pilot, is a conversational AI platform that unifies antibody and T-cell receptor (TCR) design workflows — replacing dozens of discrete bioinformatics and computational tools with a single natural-language interface. The platform combines proprietary structural modeling, variant generation, biologics optimization (for stability, expression, and manufacturability), and ML models trained on immune datasets, and is positioned to serve both nimble seed-stage biotechs and global pharma R&D organizations.
The company's commercial model combines self-serve SaaS subscription (tiered pricing on the EMLy platform) with a consultative enterprise sales motion offering guided walkthrough demos and Custom Workflows engagements (proprietary immune sequencing, functional immune discovery, antibody expression enhancement, co-complex prediction). The founding team's credentials — credited with contributions to 20+ FDA-approved therapies — anchor the credibility of the platform in real-world drug development. The most material commercial and scientific proof point is the collaboration with Oslo-listed Zelluna, whose AI-optimized TCR-NK candidate ZI-MA4-1 received UK MHRA approval for clinical testing in February 2026, followed by an expanded partnership targeting the KKLC1 cancer antigen in March 2026.
Etcembly's strategic posture is that of an early-stage, pre-funding-disclosure AI-native discovery platform. It operates from the Oxford Science Park AI cohort (joined July 2024), runs a Long-Term Survivor Study (launched September 2024) to generate proprietary immune sequencing data, and has built a partnership ecosystem including Vector Laboratories (technology integration) and Finnoah PR (communications). With 11-50 employees, no disclosed funding rounds, and only two named customers, the company remains in an early commercial phase while pursuing regulatory-grade validation through partner-led clinical programs.
Etcembly firmographics
Firmographics- Name
- Etcembly
- Legal name
- Etcembly Limited
- Website
- https://etcembly.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Etcembly is a UK-based AI-native techbio company whose EMLy Co-pilot platform unifies antibody and T-cell receptor design workflows into a single conversational interface, serving biotech and pharma R&D organizations with proprietary structural modeling, variant generation, and biologics optimization capabilities.
- Ownership category
- akta.pro rank
Etcembly industry classification
Industry- Product category
- AI Biologics Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design Services (541512)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Etcembly is headquartered
LocationHeadquarters
- HQ city
- Hanwell
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Etcembly business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- EMLy Co-pilot Platform Access: SaaS-based AI platform for biologics discovery offered via subscription with tiered pricing. The company offers guided walkthrough demos and custom workflow engagements, suggesting both self-serve and enterprise licensing models.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Etcembly product offering
Product offeringCore offering
Etcembly provides EMLy Co-pilot, an AI-powered SaaS platform that unifies biologics design workflows—including antibody, T-cell receptor (TCR), and other protein engineering—into a single conversational interface. The platform performs proprietary structural modeling, variant generation, and biologics optimisation to help scientists design development-ready therapeutic candidates. Complementing the platform, Etcembly offers Custom Workflows for bespoke AI-driven discovery services such as proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction.
Product overview
Etcembly offers EMLy Co-pilot as its core AI platform, which unifies biologics design workflows into a single conversational interface. The platform is complemented by Custom Workflows services that provide bespoke solutions including proprietary immune sequencing, functional immune discovery, and antibody expression enhancement. The product portfolio supports multiple modalities (mAbs, TCRs) across the drug discovery pipeline from target hypothesis through clinical lead optimization and CMC.
Differentiator
Problem solved
Functional benefit
Products and services
- EMLy Co-pilot An integrated AI platform that unifies biologics design workflows into a single conversational experience, enabling scientists to decode, predict, and design development-ready therapeutic candidates across target-to-hit, hit-to-lead, and clinical lead optimization stages. Supports multiple modalities including monoclonal antibodies (mAbs), T-cell receptors (TCRs), and other biologics, and is targeted at biotech and pharmaceutical R&D organizations.
- Custom Workflows Tailored AI-driven biologics discovery services for clients requiring bespoke computational workflows, including proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction. Targeted at biotech and pharma organizations needing project-specific computational biology engagements.
Quantifiable outcome
- Discovery timeline compressed from weeks to minutes
- +1 more outcomes
Companies that use Etcembly
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Etcembly technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Etcembly partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- ZellunacoreZelluna, a Norwegian biotech company listed on the Oslo Stock Exchange, collaborated with Etcembly for AI-enabled T-cell receptor engineering. The collaboration builds on their previous successful partnership that produced ZI-MA4-1, which received UK MHRA approval for clinical testing in February 2026. The expanded partnership targets the KKLC1 cancer antigen for use in allogeneic TCR-NK cell therapy platform for treating solid cancers. In-vitro data from the new KKLC1 program expected in Q4 2026.
- Finnoah PRminorManchester-based communications agency Finnoah PR was appointed by Etcembly for public relations services. Finnoah PR is described as a Manchester comms agency serving the technology and biotech sectors.
Scale indicators2 records
Recent moves5 records
Expansion highlights6 records
Etcembly competitors and assessment
Company assessmentEmerging players
- Cradle Bio: AI protein design platform helping scientists engineer biologics with improved properties. Comparable as an emerging player offering generative AI tools for protein engineering, partially overlapping Etcembly's biologics optimization capabilities.
- Antiverse: UK-based early-stage company using AI/ML to design antibody therapeutics. Comparable as an emerging AI-antibody-design peer based in the same UK ecosystem with overlapping target customers.
Direct peers
- LabGenius: UK-based AI-driven antibody discovery company combining ML, robotics, and synthetic biology. Highly comparable to Etcembly as a fellow UK techbio applying ML to antibody engineering with enterprise pharma customers.
- Insitro: AI/ML-driven drug discovery company combining ML with biological data to accelerate therapeutic development. Closely comparable to Etcembly in applying machine learning to biologics and small-molecule discovery workflows.
- Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple modalities. Directly comparable to Etcembly in using ML to design biologics (antibodies, enzymes, peptides) for pharma partners.
- BigHat Biosciences: AI-driven antibody engineering platform combining wet-lab high-throughput experimentation with ML. Highly comparable to Etcembly's EMLy platform in target customer (biologics developers), technology (ML-guided protein engineering), and modality focus (antibodies).
Others
- BenchSci: AI-powered scientific research platform for life-science R&D. Comparable as an AI-enabling layer for biotech scientists, though focused on experiment/reagent selection rather than de novo biologics design.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's protein-structure models. Comparable as a broad incumbent applying AI to biologics design, with significantly greater resources than Etcembly.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with ML across multiple therapeutic areas. Comparable as a broad incumbent using AI/ML across discovery, though with a stronger small-molecule and phenotypic-screening orientation than Etcembly.
- AbCellera Biologics: Public clinical-stage antibody discovery platform using data engineering and ML to identify antibody candidates. Comparable as a broader incumbent in ML-enabled antibody discovery serving large pharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Etcembly social profiles
Digital presenceEtcembly financial estimates
Financial estimateRevenue estimate
Valuation estimate
Etcembly leadership team
Management profileNumber of profiles
Profiles2 records
Etcembly funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Etcembly M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Etcembly
What does Etcembly do?
Etcembly provides EMLy Co-pilot, an AI-powered SaaS platform that unifies biologics design workflows—including antibody, T-cell receptor (TCR), and other protein engineering—into a single conversational interface. The platform performs proprietary structural modeling, variant generation, and biologics optimisation to help scientists design development-ready therapeutic candidates. Complementing the platform, Etcembly offers Custom Workflows for bespoke AI-driven discovery services such as proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction.
Is Etcembly a public or private company?
Etcembly is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Etcembly founded?
Etcembly was founded in 2020. It employs 11 to 50 people.
Where is Etcembly based?
Etcembly is headquartered in Hanwell, United Kingdom, in the Europe region.
How does Etcembly make money?
One revenue line is on record: EMLy Co-pilot Platform Access.
Who are Etcembly's main competitors?
Emerging players on record are Cradle Bio and Antiverse. Direct peers are LabGenius, Insitro, Generate Biomedicines and BigHat Biosciences. BenchSci is listed as an others. Broad incumbents are Isomorphic Labs, Recursion Pharmaceuticals and AbCellera Biologics.
Does Etcembly have an API?
No public API is recorded for Etcembly.
What industry is Etcembly in?
Etcembly's product category is AI Biologics Discovery Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.